Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease-Reference-Cited by-同舟云学术

Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease

Published:2018-04 Issue: Volume:22 Page:S97-S103
ISSN:1492-7535
Container-title:Hemodialysis International
language:en
Short-container-title:Hemodialysis International

Author:

Ridruejo Ezequiel¹²³^ORCID,Mendizabal Manuel²³^ORCID,Silva Marcelo O.²³

Affiliation:

1. Hepatology Section, Department of Medicine; Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno “CEMIC”; Ciudad Autónoma de Buenos Aires; Argentina

2. Hepatology and Liver Transplant Unit; Hospital Universitario Austral; Pilar; Provincia de Buenos Aires; Argentina

3. Latin American Liver Research, Educational and Awareness Network (LALREAN); Pilar; Provincia de Buenos Aires; Argentina

Publisher

Wiley

Subject

Nephrology,Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hdi.12651/fullpdf

Reference53 articles.

1. WHO. Global Hepatitis Report 2017 http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1

2. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS;Fissell;Kidney Int.,2004

3. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease;Tsui;Arch Intern Med.,2007

4. American Association for the Study of Liver Disease (AASLD) HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C 2017 http://www.hcvguidelines.org/full-report-view

5. EASL recommendations on treatment of hepatitis C 2016;European Association for Study of Liver;J Hepatol.,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection;Antiviral Drug Discovery and Development;2021

2. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease;Nefrología;2020-01

3. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease;Nefrología (English Edition);2020-01

4. High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents;International Urology and Nephrology;2019-10-14

5. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy;Cold Spring Harbor Perspectives in Medicine;2019-09-30